Pharmacotherapy of Pulmonary Hypertension / edited by Marc Humbert, Oleg V. Evgenov, Johannes-Peter Stasch.

• Preface.- Part I. Pulmonary hypertension: conceptual bases of the disease. Pulmonary hypertension: definition, classification, and epidemiology. Pulmonary hypertension: pathophysiology and signalling pathways. Pulmonary hypertension: pathology. Pulmonary hypertension: biomarkers. Pulmonary hypertension: animal models -- Part II. Pulmonary hypertension: established therapies. General supportive care. Calcium channel blockers. Prostacyclins. Endothelin receptor antagonists. Phosphodiesterase 5 inhibitors -- Part III. Pulmonary hypertension: novel pathways and emerging therapies     Soluble guanylate cyclase stimulators. Therapeutics targeting dysregulated redox equilibrium and endothelial dysfunction (NOXs, sGC activators, GSNOR). Rho-kinase inhibitors. Serotonin transporters and serotonin receptors. PDGF inhibitors. Novel anti-proliferative strategies beyond imatinib. Immunosuppressive agents. Vasoactive peptides. Inhibitors of cGMP/cAMP metabolism (MRP4, MRP5, PDE1). Old targets re-visited. Stem cells and cell based therapy -- Part IV. Conclusions and Outlook. Pulmonary hypertension: evidence-based management in the modern era and future directions.

Ämnesord

Medicine.  (LCSH)

Medical laboratories.  (LCSH)

Toxicology.  (LCSH)

Pharmaceutical technology.  (LCSH)

Internal medicine.  (LCSH)

Pneumology.  (LCSH)

Biomedicine. 

Pharmacology/Toxicology. 

Pharmaceutical Sciences/Technology. 

Internal Medicine. 

Pneumology/Respiratory System. 

Laboratory Medicine. 

Molecular Medicine. 

Publikations- och innehållstyp

RM1-950 (LCC)

MED071000 (ämneskategori)

615 (DDC)

V (kssb/8 (machine generated))